# Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

> **NCT07490002** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changhai Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Esophageal Squamous Carcinoma

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel

## Key facts

- **NCT ID:** NCT07490002
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-06
- **Primary completion:** 2028-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490002, "Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07490002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*